In 2023 Vetoquinol Celebrates Its 90th Anniversary
January 30 2023 - 12:45PM
Business Wire
The story of an incredible family saga. From a regional
pharmaceutical laboratory to a world leader in animal
health
Regulatory News:
The story of Vetoquinol (Paris:VETO) began behind a pharmacy in
the town of Lure in eastern France where Joseph Frechin produced
his human pharmaceutical products. In 1933, to help a chemist
friend, he bought a stock of 4 tonnes of oxyquinoline, an
antiseptic used in human medicine. This visionary move marked the
beginning of a family and entrepreneurial destiny.
He then had the idea of using the antiseptic properties of
oxyquinoline to treat... animals. Calling on his father, Charles, a
well-known veterinarian in the region, to test his product. It was
a complete success, an extremely effective remedy for treating
several diseases. This medicine, called "Vetoquinol", was then
marketed in various forms such as soluble tablets, gels, and
ointments.
After the Second World War, the agricultural sector had to
reconstitute livestock to feed the population. Farmers could only
achieve this goal with the help of veterinary care.
In 1962, the company expanded and added a veterinary department
called Vetoquinol to its pharmaceutical activities. At that time
more than 80 people were working for this entity.
In 1963, Etienne Frechin, son of Joseph, joined the company to
take charge of its development. A visionary, he gave new momentum
to the company, which expanded internationally. He consolidated
Vetoquinol's activities in Magny-Vernois, a village near Lure,
France. The company then had 100 employees and continued to grow.
Vetoquinol quickly established a network of subsidiaries covering
all five continents.
In April 2001, Matthieu Frechin joined his father's company and
became Vetoquinol's CEO in 2010. He now represents the 3rd
generation of Frechin’s at the helm of the company! Joseph's
intuition and Etienne's global vision, combined with Matthieu's
energy and boldness, have made the company a major player in animal
health.
The family's objective was to maintain its independence, keep
its main activity in Lure and continue its long-term growth.
Managed by a family shareholding the company combines agility and
speed thanks to its human size and strong values rooted in
entrepreneurial drive, innovation, and team spirit.
In 2006, its listing on the stock market gave Vetoquinol the
credibility and resources to become one of the world's leading
animal health companies. Its success is clear, with sales growing
by 50% between 2017 and 2022.
Today, Vetoquinol is focusing on companion animals and livestock
in three major regions of the world (Europe, the Americas and
Asia-Pacific) with the ambition of continuing to grow while
remaining a family-owned, independent, and socially responsible
company.
Its objective is to build a sustainable future by limiting its
environmental footprint to pursue its mission: “To enrich the
lives of People through dedication to animal health and
welfare”.
ABOUT VETOQUINOL Vetoquinol is a leading global animal
health company that supplies drugs and non-medicinal products for
the farm animals (cattle and pigs) and pet (dogs and cats) markets.
As an independent pure player, Vetoquinol designs, develops and
sells veterinary drugs and non-medicinal products in Europe, the
Americas and the Asia Pacific region. Since its foundation in 1933,
Vetoquinol has pursued a strategy combining innovation with
geographical diversification. The Group’s hybrid growth is driven
by the reinforcement of its product portfolio coupled with
acquisitions in high potential growth markets. Vetoquinol employed
more than 2,500 people as of December 31st, 2022.
Vetoquinol has been listed on Euronext Paris since 2006 (symbol:
VETO). The Vetoquinol share is eligible for the French PEA and
PEA-PME personal equity plans.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230130005451/en/
FOR MORE INFORMATION CONTACT:
VETOQUINOL
Group Communications Officer Resika Narain-Menigot
Tel.: +33 (0)3 84 62 57 46 resika.narain-menigot@vetoquinol.com
KEIMA COMMUNICATION
Press Relations Charles-Edouard Aubry Tel.: +33
(0)6 09 09 48 32 charles-edouard.aubry@keima.fr
Investors Relations Emmanuel Dovergne Tel.: +33
(0)6 76 94 40 87 emmanuel.dovergne@keima.fr
Vetoquinol (EU:VETO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Vetoquinol (EU:VETO)
Historical Stock Chart
From Oct 2023 to Oct 2024